We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Takeda Pharmaceutical Company Ltd | NYSE:TAK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.25 | 1.91% | 13.36 | 4,280 | 11:52:41 |
From May 2023 to May 2024
The FDA granted approval for the subcutaneous administration of Entyvio as a therapy for adults with moderate to severe ulcerative colitis. The agency had already granted approval for the drug as an IV therapy for the disease. "Takeda Gets FDA Approval for Ulcerative Colitis Therapy," at 4:43 p.m. ET on Sept. 27, didn't clarify what form of Entyvio was approved.
(END) Dow Jones Newswires
September 28, 2023 08:25 ET (12:25 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Takeda Pharmaceutical Chart |
1 Month Takeda Pharmaceutical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
